THE LEARNING SCOPE ▶ CE Offering • 1 Contact Hour

Hepatitis C Treatment

Earn 1 Contact Hour NOW!

Registration/Answer Form #400

LEARNER FEEDBACK QUESTIONS

1. A □ B □ C □ D □
2. A □ B □ C □ D □
3. A □ B □ C □ D □
4. A □ B □ C □ D □
5. A □ B □ C □ D □
6. A □ B □ C □ D □
7. A □ B □ C □ D □
8. A □ B □ C □ D □
9. A □ B □ C □ D □
10. A □ B □ C □ D □

EVALUATION

1. I can recognize people at risk for hepatitis C infection and understand hepatitis C diagnostic testing.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

2. I can recommend the approved hepatitis C therapies for naïve patients and treatment-experienced patients.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

3. I can understand the endpoints of therapy and at what time points to stop therapy due to treatment futility.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

4. The objectives relate to the overall goal of the article.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

5. The article is well-written and logically organized, and defines terms adequately.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

Evaluation

1. Which of the following is NOT a risk factor for hepatitis C:
   a. intravenous drug use
   b. intranasal cocaine use
   c. blood transfusions prior to 1992
   d. eating of contaminated foods

2. A patient was found to have a positive hepatitis C antibody. Which test confirms the diagnosis of chronic hepatitis C?
   a. alanine aminotransferase
   b. HCV-RNA by PCR
   c. HBcAb
   d. repeat HCV AB

3. The most common hepatitis C genotype seen in the U.S. is:
   a. 1
   b. 2
   c. 3
   d. 4

4. The approved therapy for hepatitis C genotype 2 is:
   a. pegylated interferon plus ribavirin for 24 weeks
   b. pegylated interferon plus ribavirin for 48 weeks
   c. pegylated interferon plus ribavirin plus boceprevir for 24 weeks
   d. pegylated interferon plus ribavirin plus telaprevir for 24 weeks

5. Which of the following naïve patients with hepatitis C genotype 1 should NOT be started on triple therapy?
   a. 55-year-old man with bridging fibrosis
   b. 45-year-old woman with diabetes and hypertension
   c. 52-year-old man with ascites
   d. 62-year-old woman with moderate disease on liver biopsy

6. In patients treated with boceprevir-based therapy, therapy should be discontinued if the HCV-RNA is:
   a. 200,000 IU/mL at treatment week 4
   b. 250 IU/mL at treatment week 12
   c. 250 IU/mL at treatment week 8
   d. 42 IU/mL at treatment week 8

7. A naïve patient on telaprevir-based therapy can receive 24 weeks of therapy if:
   a. the week 4 HCV-RNA is 900 and the week 8 HCV-RNA is undetected
   b. the week 8 HCV-RNA is 100 and the week 12 HCV-RNA is undetected
   c. the week 4 HCV-RNA is undetected and the week 8 HCV-RNA is undetected
   d. the week 8 HCV-RNA is undetected and the week 12 HCV-RNA is undetected

8. The sustained viral response of a previous null responder when treated with telaprevir-based therapy is:
   a. 6 percent
   b. 14 percent
   c. 31 percent
   d. 52 percent

9. Which of the following patients must be treated for a total of 48 weeks?
   a. naïve genotype 1 with cirrhosis
   b. naïve genotype 2 without cirrhosis
   c. partial responder to previous therapy with pegylated interferon and ribavirin
   d. previous relapser to Peg-IFN and ribavirin therapy

10. Which of the following alternative medications has been used the most to improve virological response in patients receiving antiviral therapy?
    a. silimarmin
    b. kava kava
    c. betaine
    d. vitamin D

Keep ADVANCE Coming!

This may be only a trial copy or it may be time to renew. You won’t continue to receive ADVANCE for Nurses unless you contact us for your FREE subscription.

☐ YES! I am a Nurse, sign me up!
☐ I prefer to receive a PRINT SUBSCRIPTION.
☐ I prefer to receive the DIGITAL EDITION, (e-mail address required below)
☐ I prefer to receive BOTH a print and digital edition. (e-mail address required below)

Date: ____________________
Signature (required): _________

E-mail: ____________________

JOB TITLE that best describes your position (fill in just one circle completely)

RN
☐ Director of Nursing
☐ Manager/Supervisor
☐ Nursing Administrator
☐ Nursing Faculty
☐ Private Practice
☐ Staff Development
☐ Staff Nurse
☐ Program Director

Nursing School Student
☐ LPN
Grad. date: ____________________
☐ Senior
☐ Non-Senior (Digital Only)
☐ Nursing School

LPN
☐ Manager/Supervisor
☐ Nursing Administrator
☐ Nursing Faculty
☐ Nursing/Clinical Informatics
☐ Staff Development
☐ Staff Nurse

PRACTICE SETTING that best describes your setting (fill in just one circle completely)

☐ Ambulatory
☐ Cardiovascular
☐ Cancer Management
☐ Chemical Dependency
☐ Clinical Specialist
☐ Critical Care
☐ CNNA
☐ Dermatology
☐ Dialysis
☐ Education
☐ ED/ICU
☐ Geriatrics/LTC
☐ Gynecology
☐ Home Health
☐ Hospice
☐ ICU
☐ Infection Control
☐ IV Therapy
☐ Managed Care
☐ Management/ Administrative
☐ Mental/Child
☐ Med/Surg
☐ MROG
☐ Nursing/Clinical Informatics
☐ Occupational Health
☐ Office
☐ Oncology
☐ OR/PCU
☐ Orthopedics
☐ Pediatrics
☐ Psychiatric
☐ Public Health
☐ Rehab
☐ Research
☐ Sales/Marketing
☐ School Nurse
☐ Student
☐ Substance Abuse
☐ Support Staffing
☐ Travel Nursing
☐ URSO

RN